Agilent Technologies Inc (NYSE:A) – Equities research analysts at Jefferies Financial Group lifted their FY2019 earnings per share (EPS) estimates for shares of Agilent Technologies in a research note issued to investors on Tuesday, November 20th. Jefferies Financial Group analyst B. Couillard now expects that the medical research company will earn $3.04 per share for the year, up from their previous forecast of $2.94. Jefferies Financial Group also issued estimates for Agilent Technologies’ Q4 2019 earnings at $0.87 EPS and FY2020 earnings at $3.30 EPS.
A has been the topic of several other reports. Morgan Stanley raised their price objective on Agilent Technologies from $84.00 to $86.00 and gave the company an “overweight” rating in a research report on Wednesday, October 10th. Goldman Sachs Group reissued a “buy” rating and issued a $82.00 price objective (up from $77.00) on shares of Agilent Technologies in a research report on Tuesday, September 18th. Cleveland Research lowered Agilent Technologies from a “buy” rating to a “neutral” rating in a research report on Monday, November 12th. ValuEngine raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. Finally, Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $78.75.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 19th. The medical research company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.26 billion. During the same period last year, the company posted $0.67 earnings per share. The firm’s revenue was up 8.8% compared to the same quarter last year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st will be paid a dividend of $0.164 per share. The ex-dividend date is Friday, December 28th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 annualized dividend and a dividend yield of 0.97%. Agilent Technologies’s dividend payout ratio (DPR) is currently 21.51%.
Agilent Technologies announced that its Board of Directors has authorized a stock repurchase plan on Monday, November 19th that allows the company to buyback $1.75 billion in shares. This buyback authorization allows the medical research company to purchase up to 8.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
In other news, Director Heidi Fields sold 5,482 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $67.73, for a total transaction of $371,295.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul N. Clark sold 2,876 shares of the firm’s stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $68.60, for a total value of $197,293.60. The disclosure for this sale can be found here.
Institutional investors have recently made changes to their positions in the company. SRS Capital Advisors Inc. grew its stake in shares of Agilent Technologies by 75.9% during the second quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 773 shares in the last quarter. Moneta Group Investment Advisors LLC grew its stake in shares of Agilent Technologies by 391.7% during the second quarter. Moneta Group Investment Advisors LLC now owns 6,023 shares of the medical research company’s stock valued at $158,000 after acquiring an additional 4,798 shares in the last quarter. TRUE Private Wealth Advisors acquired a new stake in shares of Agilent Technologies during the third quarter valued at about $181,000. Bray Capital Advisors grew its stake in shares of Agilent Technologies by 12,000.0% during the second quarter. Bray Capital Advisors now owns 3,025 shares of the medical research company’s stock valued at $187,000 after acquiring an additional 3,000 shares in the last quarter. Finally, AMG National Trust Bank acquired a new stake in shares of Agilent Technologies during the third quarter valued at about $212,000.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Featured Story: What is Depreciation?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.